Intrexon Corp. (XON) Sees Strong Trading Volume
Intrexon Corp. (NYSE:XON) shares saw unusually-strong trading volume on Wednesday . Approximately 1,885,159 shares were traded during trading, an increase of 45% from the previous session’s volume of 1,303,615 shares.The stock last traded at $28.23 and had previously closed at $26.23.
A number of analysts recently issued reports on XON shares. Vetr raised Intrexon Corp. from a “strong sell” rating to a “buy” rating and set a $27.01 price objective for the company in a research report on Thursday, July 28th. Zacks Investment Research raised Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 price target for the company in a research report on Tuesday, July 19th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Intrexon Corp. in a research report on Thursday, April 21st. Wunderlich reaffirmed a “buy” rating and issued a $50.00 price target on shares of Intrexon Corp. in a research report on Thursday, July 7th. Finally, Griffin Securities reaffirmed a “buy” rating and issued a $65.00 price target on shares of Intrexon Corp. in a research report on Tuesday, June 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $48.37.
The company has a 50-day moving average price of $25.16 and a 200-day moving average price of $29.69. The firm’s market cap is $3.35 billion.
Intrexon Corp. (NYSE:XON) last released its earnings results on Tuesday, May 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.35. During the same period in the previous year, the business posted $0.25 EPS. The business earned $43.40 million during the quarter, compared to analysts’ expectations of $46.26 million. The company’s quarterly revenue was up 28.4% on a year-over-year basis. Equities research analysts predict that Intrexon Corp. will post ($1.32) EPS for the current fiscal year.
In other news, CEO Randal J. Kirk bought 41,830 shares of the stock in a transaction on Friday, May 13th. The stock was purchased at an average price of $23.92 per share, for a total transaction of $1,000,573.60. The transaction was disclosed in a filing with the SEC, which is available at this link.
A number of institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley boosted its position in Intrexon Corp. by 12.6% in the fourth quarter. Morgan Stanley now owns 3,162,236 shares of the company’s stock worth $95,342,000 after buying an additional 354,559 shares during the period. Trexquant Investment LP purchased a new position in Intrexon Corp. during the fourth quarter worth about $2,590,000. New York State Common Retirement Fund boosted its position in Intrexon Corp. by 30.1% in the fourth quarter. New York State Common Retirement Fund now owns 212,875 shares of the company’s stock worth $6,418,000 after buying an additional 49,290 shares during the period. Swiss National Bank boosted its position in Intrexon Corp. by 3.8% in the fourth quarter. Swiss National Bank now owns 62,500 shares of the company’s stock worth $1,884,000 after buying an additional 2,300 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its position in Intrexon Corp. by 261.8% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 81,072 shares of the company’s stock worth $2,444,000 after buying an additional 58,667 shares during the period.
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.